Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
J Allergy Clin Immunol. 2019 Oct;144(4):875-881. doi: 10.1016/j.jaci.2019.08.022.
The idiosyncratic activation of mast cells (MCs) in response to administration of nonselective COX inhibitors is a cardinal feature of aspirin-exacerbated respiratory disease (AERD). Older studies using MC-stabilizing drugs support a critical role for MCs and their products in driving the severe eosinophilic inflammation and respiratory dysfunction that is typical of AERD. Because patients with AERD react to all nonselective COX inhibitors regardless of their chemical structure, the mechanism of MC activation is not caused by classical, antigen-induced cross-linking of IgE receptors. Recent studies in both human subjects and animal models have revealed a complex and multifactorial process culminating in dysregulation of MC function and an aberrant dependency on COX-1-derived prostaglandin E to maintain a tenuous homeostasis. This article reviews the factors most likely to contribute to MC dysregulation in patients with AERD and the potential diagnostic and therapeutic implications.
肥大细胞(MCs)在非选择性环氧化酶抑制剂给药时的独特激活是阿司匹林加重的呼吸道疾病(AERD)的一个主要特征。使用 MC 稳定剂的早期研究支持 MC 及其产物在驱动 AERD 中典型的严重嗜酸性粒细胞炎症和呼吸功能障碍方面的关键作用。由于 AERD 患者对所有非选择性 COX 抑制剂均有反应,无论其化学结构如何,因此 MC 激活的机制不是由经典的、抗原诱导的 IgE 受体交联引起的。最近在人体和动物模型中的研究揭示了一个复杂的、多因素的过程,最终导致 MC 功能失调,并异常依赖 COX-1 衍生的前列腺素 E 来维持脆弱的体内平衡。本文综述了最有可能导致 AERD 患者 MC 失调的因素,以及潜在的诊断和治疗意义。